Details for Patent: 8,545,402
✉ Email this page to a colleague
Which drugs does patent 8,545,402 protect, and when does it expire?
Patent 8,545,402 protects ABILIFY MYCITE KIT and is included in one NDA.
This patent has twenty-seven patent family members in seventeen countries.
Summary for Patent: 8,545,402
| Title: | Highly reliable ingestible event markers and methods for using the same |
| Abstract: | Ingestible event markers having high reliability are provided. Aspects of the ingestible event markers include a support, a control circuit, a first electrochemical material, a second electrochemical material and a membrane. In addition, the ingestible event markers may include one or more components that impart high reliability to the ingestible event marker. Further, the ingestible event markers may include an active agent. In some aspects, the active agent, such as a pharmaceutically active agent or a diagnostic agent may be associated with the membrane. |
| Inventor(s): | Hafezi; Hooman (Redwood City, CA), Au-Yeung; Kityee (San Francisco, CA), Duck; Robert (San Francisco, CA), Holen; Maria (Santa Clara, CA), Robertson; Timothy (Belmont, CA), Costello; Benedict (Berkeley, CA) |
| Assignee: | Proteus Digital Health, Inc. (Redwood City, CA) |
| Application Number: | 12/744,642 |
|
Patent Claim Types: see list of patent claims | Dosage form; |
Drugs Protected by US Patent 8,545,402
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Otsuka | ABILIFY MYCITE KIT | aripiprazole | TABLET;ORAL | 207202-001 | Nov 13, 2017 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| Otsuka | ABILIFY MYCITE KIT | aripiprazole | TABLET;ORAL | 207202-002 | Nov 13, 2017 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| Otsuka | ABILIFY MYCITE KIT | aripiprazole | TABLET;ORAL | 207202-003 | Nov 13, 2017 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| Otsuka | ABILIFY MYCITE KIT | aripiprazole | TABLET;ORAL | 207202-004 | Nov 13, 2017 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| Otsuka | ABILIFY MYCITE KIT | aripiprazole | TABLET;ORAL | 207202-005 | Nov 13, 2017 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 8,545,402
| PCT Information | |||
| PCT Filed | April 27, 2010 | PCT Application Number: | PCT/US2010/032590 |
| PCT Publication Date: | November 11, 2010 | PCT Publication Number: | WO2010/129288 |
International Family Members for US Patent 8,545,402
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Brazil | 122013009559 | ⤷ Sign Up | |||
| Brazil | PI1015298 | ⤷ Sign Up | |||
| Chile | 2011002700 | ⤷ Sign Up | |||
| China | 102458236 | ⤷ Sign Up | |||
| Costa Rica | 20110624 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
